Outpatient treatment of decompensated heart failure: A systematic review and study level meta-analysis

Jameela Bahar1, Amna Rahman1, Grace W.Y. Wong2, Rajiv Sankaranarayanan3,4, Fozia Z. Ahmed5,6, Rebecca Taylor1, Ahmet Fuat7, Iain Squire8, John G.F. Cleland9, Gregory Y.H. Lip10,11, James H.P. Gamble12, Sundas Masudi1, Prince Josiah S. Joseph1 and Kenneth Y.K. Wong1,4*

1Department of Cardiology, Lancashire Cardiac Centre, Blackpool, UK; 2Lancashire Cardiac Centre Patient Public Involvement Group, Lancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK; 3Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK; 4Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK; 5Keele University, Keele Cardiovascular Research Group, Keele, UK; 6Department of Cardiology, Manchester University Hospitals NHS Foundation Trust, Manchester, UK; 7Durham University, UK; 8NIHR Cardiovascular Research Centre, Glenfield Hospital, Leicester, UK; 9British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; 10Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK; 11Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; and 12Oxford Heart Centre, John Radcliffe Hospital, Oxford, UK

Abstract

Patients with acutely decompensated heart failure (ADHF) are usually admitted to hospital for management. There is growing interest in delivering intravenous (IV) diuretic therapy at home, in the community or at hospital day-care units; the safety and effectiveness of outpatient-based management (OPM) for ADHF has not been established. We conducted a systematic literature review and meta-analysis to investigate the short-term safety and effectiveness of OPM compared with inpatient management (IPM) of ADHF. Pre-specified endpoints were 30 day mortality and 30 day hospitalization. The meta-analysis was conducted using RevMan 5.4 software. Twenty-nine studies of OPM were identified, including 7683 patients. Only five studies directly compared OPM (n = 1303) with IPM (n = 2047), including three observational studies, and two randomized controlled trials (RCTs). The other 24 studies only stated OPM outcomes. For the five studies comparing IPM versus OPM, patients were generally aged >75 years and of similar age for each strategy, with a similar proportion of men (56%). In a study-level, aggregate analysis, 30 day all-cause mortality was 9.3% (121/1303) for OPM, compared with 15.6% (320/2047) for IPM [OR 0.29 (95% CI 0.09, 0.93), P = 0.04]. Four studies reported 30 day all-cause hospitalization; 22.0% for IPM versus 16.8% for OPM [OR 0.73 (95% CI 0.61, 0.89), P = 0.001]. In the two RCTs, we found no difference in 30 day mortality or hospitalization. In observational studies, OPM of ADHF is associated with lower 30 day hospitalization and lower 30 day mortality; such differences were not observed in two small, single-centre RCTs. A substantial, multicentre RCT is required to confirm the safety and effectiveness of OPM for ADHF.

Keywords outpatient IV diuretics; acute decompensated heart failure; systematic review; meta-analysis

Received: 30 November 2022; Revised: 19 March 2024; Accepted: 24 April 2024

*Correspondence to: Kenneth Y. K. Wong, Department of Cardiology, Lancashire Cardiac Centre, Blackpool, UK. Email: dr.wong@nhs.net

Introduction

Acute heart failure (AHF) is the primary reason for about 100 000 hospitalizations each year in the United Kingdom,1 with a median length of stay of 5 days for those patients not seen by specialists and 8 days for those seen by heart failure (HF) specialists or in cardiology wards. Inpatient mortality was 10%.2 For some patients with AHF, alternatives to hospitalization may be appropriate. Indeed, some centres have initiated outpatient intravenous (IV) diuretic programmes (furosemide lounges/day-case/ambulatory care unit in hospital, in the community or at home).3,4 Recently, a systematic review of 11 observational studies reported that outpatient management (OPM) with intravenous (IV) diuretics was safe and associated with lower mortality rates than inpatient management (IPM). However, only patients
who were considered to have a good short-term prognosis received OPM, potentially biasing the results. The review highlighted the need to consider other outcomes, including quality of life and re-hospitalization rates, and concluded that a sufficiently powered randomized controlled trial (RCT) was required to demonstrate the safety and utility of OPM. We recently conducted a pilot RCT including 24 patients and became aware of another small RCT. Accordingly, we decided to update the existing systematic review.

Objectives

This systematic literature review and meta-analysis investigates the effectiveness of OPM of AHF using IV and subcutaneous diuretics compared with IPM (considered current standard of care). The primary outcomes of interest were 30 day mortality and 30 day re-hospitalization.

Methods

Literature search strategy

Relevant publications were identified by online search engines (Ovid and Scopus) and reference lists from recent systematic reviews and abstracts/conference proceedings. Our database search terms incorporated: Heart failure, Diuretics, Outpatient, Intravenous and Subcutaneous ‘heart failure’ AND ‘diuretics’ AND ‘outpatient’ AND ‘intravenous’ OR ‘subcutaneous’.

Inclusion criteria consisted of patients with acute/worsened HF and publications written in English. There was no limit applied to the duration of follow-up or the sample size, but case reports \((n = 1)\) were excluded. Reviews, summaries and book chapters were also excluded.

Study selection and data extraction

Two first-authors (A. R and J. B.) independently screened the titles and abstracts of all articles found by searches to identify potentially eligible publications, for which full texts were subsequently obtained and reviewed. Where uncertainty existed, the senior author (K. Y. K. W.) was consulted. Data were then extracted (A. R. and J. B.), including baseline clinical characteristics, selection criteria (inclusion and exclusion), study measurements, treatment plans and outcomes [all-cause and HF hospitalizations, mortality, other adverse events, and New York Heart Association (NYHA) class]. Observational studies were assessed for risk of bias by the reviewing authors (A. R. and J. B.) using the six factor Quality in Prognosis Studies (QUIPS) tool. RCTs were assessed using the Risk of Bias 2 (RoB2) tool. Pre-specified endpoints were 30 day mortality and 30 day hospitalization.

Meta-analysis methodology

Data synthesis

Data from eligible trials were entered into the RevMan 5.4 software package. Where applicable, for dichotomous data (30 day mortality and 30 day rehospitalization), the odds ratio (OR) and 95% confidence intervals (CIs) were calculated. The \(I^2\) statistic was used to quantify heterogeneity. The results from the trials were pooled using a fixed effects model if the \(I^2\) statistic (heterogeneity) were sufficiently low. If the \(\chi^2\) statistic was \(P < 0.10\), a random effect model was used to allow generalization of the results.

In addition, we performed an aggregate analysis for all the OPM studies and the five studies comparing OPM with IPM (Figure S1): weighted mean age and % male patients were calculated for both OPM and IPM.

Results

Our systematic literature search identified 194 published studies, of which 165 publications were excluded. Thus, 29 publications met the inclusion criteria, studying OPM for AHF using parenteral diuretics (Figure 1). The studies included 9730 patients, 7683 who had OPM and 2047 who had IPM.

Of the 29 studies, 5 compared OPM with IPM for the pre-specified endpoints of 30 day mortality and hospitalization. This included three observational studies, two of which were conference proceedings, and two small single-centre RCTs with fewer than 100 patients.

There was significant heterogeneity amongst studies in baseline clinical characteristics (Table 1 and S1A). With the exception of one observational study, all studies enrolled more men than women. Patients who received OPM were younger (62 years) and less likely to be women (37%) than those who received IPM (77 years and 44%, respectively). The diuretic regime and duration of follow up in each study are summarized in Table S1B. Few studies provided information about changes in plasma concentrations of natriuretic peptides (6/29) and NYHA class before and after treatment (4/29) (Table S2). Table S2 summarizes the endpoints reported in each study.

Thirty day mortality and 30 day hospitalization

Based on an analysis of aggregated data from the publications included in this systematic review which included
mortality data ($n = 13$), overall, 30 day mortality was 8.9% for OPM (180 deaths from 2026 patients) (Table 2).

From the five publications which compared OPM with IPM, 121/1303 (9.3%) who received OPM died within 30 days, compared with 320/2047 (15.6%) for IPM (Figures 2 and S2A,B). For these five studies, the IPM cohort were on average only 2 years older (mean age 77 vs. 75 in the OPM studies) with a similar proportion of male patients (55.5 vs. 55.6%). The three observational studies showed lower mortality for OPM compared with IPM (9.5% vs. 16.0%), but the two RCTs did not (0 vs. 0 in Hamo et al.’s trial of 94 patients in the United States; $15$ and 7.7% vs. 9.1% in Wong et al.’s trial in the United Kingdom).$14$

Using data from the studies that assessed these endpoints, all-cause and HF 30 day rehospitalization were 16% (986/6268) and 13.0% (668/5162) for OPM.$12$-$15$,17-$23$ Four publications comparing OPM- versus IPM-reported 30 day hospitalization.$12$-$15$ Of the OPM cases, 206/1224 (16.8%) were hospitalized within 30 days versus 433/1972 (22%) IPM cases. OPM was associated with lower 30 day hospitalization risk [OR 0.73 (95% CI 0.61, 0.89), $P = 0.001$] (Figure 3 and S3A,B).

Five publications reporting a composite outcome of 30 day death or hospitalization,$11$,15 showed that in 149 patients receiving OPM, 33 died or were admitted within 30 days (22%).

The risk of bias was deemed lower in clinical trials (Table S3A) compared with the observation studies (Table S3B). We found better outcomes for patients receiving OPM for AHF in observation studies, but this was not replicated in two small single-centre RCTs.

**Randomized trials**

In the first UK single-centre feasibility RCT of 24 patients, patients treated by OPM had significantly more days alive out of hospital (within 30 days of randomization), with no excess mortality observed (1/11 vs. 1/13).$14$ No excess mortality was observed up to 60 days of follow-up (2/11 vs. 2/13).$14$ In this RCT, Adult State Hope scores were increased more with OPM within 30 days but dropped to lower levels than IPM by 60 days possibly because numerically more OPM patients were admitted within 60 days (6/13 patients randomized to OPM vs. 2/11 inpatients).$24$ More outpatients...
Table 1  Study Design and Patient Demographics of the studies included in the meta-analysis

<table>
<thead>
<tr>
<th>Author et al (year)</th>
<th>Study type</th>
<th>Inclusion</th>
<th>Exclusion</th>
<th>No. patients</th>
<th>Age</th>
<th>Sex (male)</th>
<th>Aetiology</th>
<th>Mean LVEF (%)</th>
<th>NYHA class</th>
<th>Renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hamo et al (2021)</td>
<td>Single centre RCT (OPM vs. IPM) (US)</td>
<td>Patients &gt;18 years old with known heart failure pathophysiology and clinical features</td>
<td>Significant comorbid condition</td>
<td>94</td>
<td>63.8 ± 12.9</td>
<td>56.4%</td>
<td>NA</td>
<td>33.5 ± 19.3</td>
<td>II 12.9%</td>
<td>II 26.9% III 58.1% IV 29.8 ± 14 mmol/L BUN 29.8 ± 14 mmol/L Serum creatinine 1.27 ± 0.42 mg/dL</td>
</tr>
<tr>
<td>Ahmed et al (2021)</td>
<td>Single-centre observation study (OPM vs. IPM) (UK)</td>
<td>Adults in the community not responding to increasing doses of oral diuretic treatment who are willing and able to complete IV diuretic decompensation treatment on an outpatient basis</td>
<td>Patients with hemodynamic instability and signs of shock. Or secondary causes of decompensation</td>
<td>154 (IP = 75 and OP = 79)</td>
<td>IP—72 (36–94) OP—77 (49–93)</td>
<td>IP—60% (n = 45) OP—57% (n = 45)</td>
<td>IPs with HFrEF 74.7% (n = 56) OPs with HFrEF 46.8% (n = 37)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Salmon et al (2021)</td>
<td>Single-centre observation study (OPM vs. IPM) (UK)</td>
<td>NA</td>
<td>NA</td>
<td>2901</td>
<td>IP—77.1 ± 10.2  OP—74.2 ± 9.1</td>
<td>IP—55.4% OP—57.1%</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Wong et al (2021)</td>
<td>Single-centre pilot RCT (OPM vs. IPM) (UK)</td>
<td>NA</td>
<td>NA</td>
<td>IP (n = 11) OP (n = 13) N = 24</td>
<td>IP 81.8 (10.4) OP 70 (16.0)</td>
<td>IP 36.4% OP 76.9%</td>
<td>IHD: IP 18.2% and OP 7.7%</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Thomas et al (2019)</td>
<td>Single-centre observational study (OPM vs. IPM) (UK)</td>
<td>Exacerbation of heart failure needing diuretics</td>
<td>NA</td>
<td>206 patients (208 admissions) IP—36 (17.3%), not admitted—172 (82.7%)</td>
<td>IP—78.3 ± 15.2 Not admitted—78.8 ± 12.0</td>
<td>IP—18 (50%), not admitted—77 (44.8%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: IPM, inpatient management; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; OPM, outpatient-based management; RCT, randomized controlled trial.
had increased total well-being scores by 60 days ($P = 0.04$) and OPM was associated with estimated mean cost savings of £2,658 (95% central range 460–4857) per patient.\textsuperscript{14,24,25}

A second small, single-centre trial (OUTLAST)\textsuperscript{15} in the United States demonstrated that IV furosemide was more effective than IV saline at reducing 30 day rehospitalization for HF (3.7% vs. 23%, $P = 0.037$). No significant differences in clinical outcomes were reported between the groups.

In addition, we also found lower HF hospitalization for OPM was observed in the RCT by Hamo et al.\textsuperscript{15} [16.7% (6/36) vs. 3.7% (1/27)]. In the pilot RCT in the United Kingdom, Wong et al.\textsuperscript{14} found numerically higher HF hospitalization in the OPM group [9.1% (1/11) vs. 15.4% (2/13)] (IPM vs. OPM). According to the detailed OUTLAST study protocol (https://doi.org/10.1371/journal.pone.0253014.s007—document), the ‘standard of care arm will be admitted or discharged from the emergency room based on the discretion of the physicians involved. If admitted, the subject will be treated in the usual manner.’ Thus, it is possible that at least a proportion of patients randomized to standard care (IPM) in OUTLAST were discharged from the emergency room, suggesting that they may be less sick than Wong et al.’s cohort. Similarly, it should be noted that the higher 30 day all-cause hospitalization in patients randomized to OPM in the small
Discussion

The key finding of our study-level aggregate analysis is that the outpatient management for acute decompensated HF was associated with lower 30 day mortality compared with standard inpatient care [9.3% vs. 15.6% (5 studies)]. However, in our analysis lower mortality for OPM compared with IPM was seen only in observational studies [9.5% vs. 16.0% (3 studies)]. In contrast, there was no significant difference between the OPM and IPM 30 day mortality between the two small single-centre trials [0 vs. 0 in Hamo et al.’s trial of 94 patients in the United States,15 and 1/13 (7.7%) vs. 1/11 (9.1%) in Wong et al.’s trial in the United Kingdom].14 This finding could indicate a degree of selection bias in the observational studies of OPM although it is likely that the two small trials do not have sufficient statistical power to detect mortality. Further, the inclusion criteria for OPM services are likely designed in such a way to be biased in favour of selecting patients at low risk of mortality, complication and rehospitalization.

In the small RCT of 24 patients in the United Kingdom, 4/13 (30.8%) of OPM were hospitalized within 30 days versus 2/11 (18.2%) of inpatients.14 In contrast, the US RCT reported lower 30 day hospitalization in the OPM cohort (7.4% vs. 27.8%),15 which is in keeping with lower 30 day hospitalization in favour of OPM reported in the two observational studies (16.9% vs. 21.9%).12,13 However, according to the detailed study protocol of the US RCT, the standard of care arm would be admitted or discharged from the emergency room based on the discretion of the physicians involved. If admitted, the subject would be treated in the usual manner, but there were no details on what proportion of patients in the standard of care group were admitted to hospital receiving IV diuretics. It should also be noted that comparing these studies is difficult with the different healthcare systems.15

Strengths and limitations

In Wierda et al.’s review,5 the authors excluded research in emergency departments or observation units and studies where only the abstract was available. We have attempted to include abstracts/conference proceedings as well as searched reference list from reviews.5,6 Nevertheless, as with all systematic reviews, this is still prone to potential publication bias. Moreover, one must be cautious interpreting aggregate analyses that included both RCTs and observational studies, especially given the greater influence of Salmon et al.’s observation study as indicated by the weightings in Figures 2 and 3. Although Salmon et al. carries a big weighting in the 30 day mortality data, it is evident that the smaller observation studies outcomes also appear statistically significantly better for OPM. In Wong et al.’s small trial, there was numerically lower 30 day mortality (but not statistically significant). However, Wong et al.’s small trial suggested there may be a signal of concern with numerically higher 30 day hospitalization in patients randomized to OPM. Nevertheless, all the observation studies and Hamo’s small trial suggest OPM is associated with reduced 30 day hospitalization. Thus, meta-analysing all the trials and observation studies may dampen the signal of concern.

It is possible that observational studies showed better outcomes in OPM groups as patients with fewer comorbidities were selected. Two small RCTs do not have enough patients to draw any meaningful conclusions. This is why we urgently need a large randomized trial to inform future HF international guidelines. Heterogeneity may render the pooled effects unreliable. Even amongst the observational studies comparing IPM with OPM, there was significant heterogeneity (P = 0.0007) (Figure S2A). We have therefore used a random effect model to potentially improve generalization of the results. In this study level meta-analysis, we have attempted to compare age and gender proportion in the studies that directly compared OPM with standard inpatient care, to assess possible selection bias. However, there are other sources of heterogeneity which we are unable to fully examine in this study-level meta-analysis. It is also important to note that many studies failed to report consistent patient BNP levels, which is known to be strongly associated with mortality.

A trend of expansion of OPM despite limited evidence from RCTs

Wierda’s systematic review in 2020 reported that OPM is safe with some observational data suggesting that OPM was associated with relatively low mortality rates; however, one major limitation was the absence of comparison with inpatients.5

In the United States, of over 1.1 million unique HF visits, across >11 000 hospitals and outpatient clinics, 1% received outpatient IV diuretics in 2015.26 This has doubled compared with 2006 before the ‘Hospital readmissions reduction programme’ in 2012. Nearly 19% of hospitals administered outpatient IV diuretics.26 There was a decrease in hospitalization to less than 30%, and a slight increase in observation units to around 2%, whereas the emergency department discharges stayed around 4.5% and...
standard clinic visits accounted for >60%. This US trend may be driven by reimbursement rules, which do not provide institutional reimbursement for HF patients who are readmitted within 30 days.

In the United Kingdom, OPM service also appeared to have gained popularity fairly quickly according to two surveys. An estimated 25,485 patients per year (median 600, interquartile range [IQR] 295–800) per site) received inpatient care for ADHF while 2731 per year patients (median 50 (7–100) per site) received OPM for AHF, representing 9.7% of total ADHF population in the 2021 survey. The 2021 survey also confirms there is uncertainty/equipoise amongst the HF community in the United Kingdom about whether to develop this service.

Ambulatory emergency care is an increasingly prevalent model of acute care. Although the potential to manage acute HF in ambulatory care is recognized, there are no standardized guidelines for how to achieve this.

Future research

We hope to perform a patient-level meta-analysis of studies comparing IPM versus OPM and apply artificial intelligence/machine learning algorithms to produce a risk score to predict likelihood of success of OPM. This patient-level meta-analysis will also enable us to fully investigate sources of heterogeneity which might include age, gender, renal function, frailty, BNP/NTproBNP, ejection fraction, sodium and haemoglobin. This study will provide vital data for the next steps towards precision medicine in this field. Furthermore, improvements in quality of life can be measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ) to identify any differences between OPM and IPM.

The small pilot trial in Blackpool suggested that OPM is effective, safe and cost effective and is a strategy favoured both by patients and carers. Importantly, patients randomized to OPM appeared to enjoy an improvement of their mental well-being. OPM was estimated to save the NHS in excess of £2600 per patient compared with IPM. Although patients randomized to OPM appeared to have increased levels of hope initially, by 60 days follow-up, their levels of hope dropped possibly because there were numerically (albeit not statistically significantly) higher number of readmissions by 60 days. In our present systematic review and aggregate analysis of the 29 studies, HF hospitalization was lower in the OPM group within 30 days (13% vs. 16%). The US pilot trial also reported lower 30 day HF hospitalization for OPM 3.7% (1/27) versus 17% (6/36). The planned large multicentre trial will help to resolve the uncertainties HF services have regarding whether to develop outpatient based IV diuretic treatment for AHF.

Patient public involvement

The Lancashire Cardiac Centre Patient Public Involvement (PPI) group consists of patients, carers and members of the public diversified in age, gender and ethnicity. This meta-analysis is considered to be very important because patients have indicated that it is more meaningful to feel well and be out of hospital rather than simply staying alive.

Wong et al.’s small pilot trial suggests that patients who receive OPM enjoy more days alive outside of hospital but signals a potentially higher risk of 30 day hospitalization.

Future research

We hope to perform a patient-level meta-analysis of studies comparing IPM versus OPM and apply artificial intelligence/machine learning algorithms to produce a risk score to predict likelihood of success of OPM. This patient-level meta-analysis will also enable us to fully investigate sources of heterogeneity which might include age, gender, renal function, frailty, BNP/NTproBNP, ejection fraction, sodium and haemoglobin. This study will provide vital data for the next steps towards precision medicine in this field. Furthermore, improvements in quality of life can be measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ) to identify any differences between OPM and IPM.

Conclusions

Outpatient IV diuretics for acute/worsening HF appears safe and effective in observation studies and two small single-centre RCTs although one of the small trials suggests possible increase in 30 day hospitalization in patients randomized to OPM. A large prospective multicentre RCT is required to determine safety, clinical effectiveness and cost effectiveness, in order to inform international HF guidelines.

Sources of funding

This work was supported by British Heart Foundation Clinical Research Collaborative to K.Y.K.W. and the University of Liverpool INSPIRE to J. B. and A. R. (joint first authors). We are also grateful for the funding of the open access publication article processing fees by the Manchester University NHS Foundation Trust.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Identifying and comparing OPM vs IPM papers and statistics.

Figure S2. Forrest Plots showing 30-day mortality data papers included in the meta-analysis.
Figure S2A. 30-day mortality data of the observational papers included in the meta-analysis.

Figure S2B. 30-day mortality data of the randomized control trial papers included in the meta-analysis.

Figure S3. Forrest Plots showing 30-day hospitalization data papers included in the meta-analysis.

Figure S3A. 30-day hospitalization data of the observational papers included in the meta-analysis.

Figure S3B. 30-day hospitalization data of the randomized control trial papers included in the meta-analysis.

Table S1. A summary of the papers identified in the literature review.

Table S1A. Selection criteria and patient characteristics of papers included in the meta-analysis.

Table S1B. An overview of study protocols and treatment regimes of papers identified in the literature review.

Table S2. Endpoints and clinical study outcomes of papers identified in the literature review.

Table S3. Quality assessments using objective risk of bias tools.

Table S3A. A Quality assessment of Randomized control trials reviewed using the RoB2 tool.

Table S3B. A Quality assessment of the Observational studies reviewed using QUIP’s tool.

References


ESC Heart Failure (2024)
DOI: 10.1002/ehf2.14841